Opening book details…
Can I read EGFR Signaling Networks in Cancer Therapy || on EtoBox?
EGFR Signaling Networks in Cancer Therapy || by Antony W. Burgess PhD, Thomas P.J Garrett PhD (auth.), John D. Haley, William John Gullick (eds.) is a medicine available to read on EtoBox.
What is EGFR Signaling Networks in Cancer Therapy || about?
The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies. Over decades of study, the EGF receptor structure, its ligand binding domains, the physical biochemistry underlying its intrinsic tyrosine kinase catalytic function and the modular interactions with SH2, PTB, and SH3 domain containin
Who reads EGFR Signaling Networks in Cancer Therapy ||?
It is typically read by working professionals who need an authoritative practice reference.
Common subject areas: medicine, law, business, engineering.
- Author
- Antony W. Burgess PhD, Thomas P.J Garrett PhD (auth.), John D. Haley, William John Gullick (eds.)
- Publisher
- Humana Press
- Published
- 2008
- Language
- EN
- ISBN
- 9781597453561
- Category
- medicine
- Subjects
- Medical, Clinical Medicine, Medicine
- Updated
- 2026-03-24
More by Antony W. Burgess PhD, Thomas P.J Garrett PhD (auth.), John D. Haley, William John Gullick (eds.)
Similar books
- Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development) — Gary K. Schwartz (2004)
- Molecularly Targeted Therapy for Childhood Cancer — William L. Carroll, Rob Pieters (auth.), Peter J. Houghton, Robert J. Arceci (2010)
- Cancer Signaling, Enhanced Edition : From Molecular Biology to Targeted Therapy — Müller, Oliver; Stocking, Carol; Wagener, Christoph (2017)
- Advances in Cancer Therapy — edited by Hala Gali-Muhtasib (2011)
- EGFR-Directed Therapy in Lung Cancer — So Yeon Kim, Daniel B. Costa, Daisuke Shibahara, Susumu Kobayashi & Balazs Halmos (2023)
- Advances in Targeted Cancer Therapy (Progress in Drug Research, 63) — Richard M. Schultz (auth.), Prof. Dr. Paul L. Herrling, Alex Matter M.D., (2005)